|
WO2021081207A1
|
|
Glp-1r modulating compounds
|
|
WO2021067181A1
|
|
Hbv vaccines and methods treating hbv
|
|
WO2021034804A1
|
|
Pharmaceutical formulations of tenofovir alafenamide
|
|
WO2021030438A1
|
|
Compounds for inhibition of alpha 4 beta 7 integrin
|
|
WO2021030142A1
|
|
Thienopyrimidine derivatives as acc inhibitors and uses thereof
|
|
WO2021011891A1
|
|
Long-acting formulations of tenofovir alafenamide
|
|
US2021017255A1
|
|
Hiv vaccines and methods of making and using
|
|
US2021017170A1
|
|
Processes for preparing toll-like receptor modulator compounds
|
|
WO2020263830A1
|
|
Flt3l-fc fusion proteins and methods of use
|
|
WO2020252151A1
|
|
Cot modulators and methods of use thereof
|
|
WO2020237027A1
|
|
Combination of a tlr7 modulating compound and an hiv vaccine
|
|
US2020392153A1
|
|
Substituted eneoxindoles and uses thereof
|
|
US2020368347A1
|
|
Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies
|
|
US2020345699A1
|
|
Hiv protease inhibitors
|
|
US2020347051A1
|
|
Solid forms of a toll-like receptor modulator
|
|
US2020345738A1
|
|
Solid forms of a toll-like receptor modulator
|
|
WO2020214647A1
|
|
Solid forms of an hiv protease inhibitor
|
|
WO2020197991A1
|
|
Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
|
|
US2020315972A1
|
|
Formulations of a compound and uses thereof
|
|
WO2020176510A1
|
|
Protein kinase c agonists
|
